Program
dupilumab
Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageDupilumab: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 529 open or running | phase 4since Jul 16, 2019 | Mar 9, 2011 | Feb 7, 2027phase 4 · NCT07905547 |
| Regeneron Pharmaceuticalsits history only | 404 open or running | phase 4since Dec 17, 2019 | Nov 10, 2009 | Apr 24, 2027phase 4 · NCT06572228 |
| Andover Eye Associates | 11 open or running | phase 2since Mar 2, 2020 | Mar 2, 2020 | none ahead |
Also a collaborator on its studies: Aimmune Therapeutics and Statistics & Data.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Andover Eye Associates only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2020First study: phase 2 study in Atopic KeratoconjunctivitisFirst studyNCT04296864 · 42 planned · United States
TargetBeta
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule
Other programs on IL4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| drotokibart | Jiangsu HengRui Medicine | phase 3 | 8 |
| TQH2722 | Sino Biopharmaceutical | phase 3 | 7 |
| SHR-1819 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
The one study Andover Eye Associates leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04296864Atopic Keratoconjunctivitis · United States | 2 | Recruiting | Jan 2025 | 42 |
How it is read
Names in the registry
- “Dupilumab”, 55 entries
- “Dupilumab SAR231893”, 13 entries
- “dupilumab”, 10 entries
- “Dupilumab (SAR231893)”, 5 entries
- “REGN668”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 32 studies
- Asthma, 17 studies
- Eosinophilic Esophagitis, 5 studies
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.